TNF and Fulminant hepatitis: The nanocomplex was intravenously injected into mice to cure LPS-related fulminant hepatitis, which resulted in not only suppressing the production of nitric oxide and TNF-α in LPS-stimulated NR8383 cells, but also attenuating the levels of TNF-α, AST, and ALT in vivo, consequently, enhancing the survival rate of mice model [77].